Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics

Affiliations

¹ Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. bicarter@mdanderson.org.
² Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁵ Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
⁶ Oncology Research, Amgen Inc, Thousand Oaks, CA, USA.
⁷ Amgen Inc, Thousand Oaks, CA, USA.
⁸ MLL Munich Leukemia Laboratory, Munich, Germany.
⁹ Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. mandreef@mdanderson.org.

Published Erratum

Bing Z Carter et al. Blood Cancer J. 2023.

. 2023 May 17;13(1):80.

doi: 10.1038/s41408-023-00857-z.

¹ Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. bicarter@mdanderson.org.
² Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁵ Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
⁶ Oncology Research, Amgen Inc, Thousand Oaks, CA, USA.
⁷ Amgen Inc, Thousand Oaks, CA, USA.
⁸ MLL Munich Leukemia Laboratory, Munich, Germany.
⁹ Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. mandreef@mdanderson.org.

No abstract available

Erratum for

Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics.
Carter BZ, Mak PY, Tao W, Ayoub E, Ostermann LB, Huang X, Loghavi S, Boettcher S, Nishida Y, Ruvolo V, Hughes PE, Morrow PK, Haferlach T, Kornblau S, Muftuoglu M, Andreeff M. Carter BZ, et al. Blood Cancer J. 2023 Apr 24;13(1):57. doi: 10.1038/s41408-023-00830-w. Blood Cancer J. 2023. PMID: 37088806 Free PMC article.